What is Zalanzo used for?

- Treatment of duodenal and gastric ulcer - Treatment of reflux oesophagitis - Prophylaxis of reflux oesophagitis - Eradication of Helicobacter pylori ( H. pylori ) concurrently given with appropriate antibiotic therapy for treatment of H. pylori -associated ulcers - Treatment of NSAID-associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment - Prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk (see section

What pharmaceutical form is Zalanzo available in?

Zalanzo: Kapsułki dojelitowe, twarde 15 mg (doustna)

Is Zalanzo OTC or prescription only?

Zalanzo requires a doctor's prescription.

What are the side effects of Zalanzo?

Frequencies are defined as common (> 1/100, 1/1,000, 1/10,000, <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). Common Uncommon Rare Very rare Not known Blood and lymphatic system disorders Thrombocytopenia, eosinophilia, leucopenia Anemia Agranulocytosis , pancytopenia Immune system disorders Anaphylactic shock Metabolism and nutrition disorders Hypomagnesaemia ( see section 4.4 ) Psychiatric disorders Depression In

Who should NOT take Zalanzo?

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Does Zalanzo interact with other medications?

Effects of lansoprazole on other medicinal products Medicinal products with pH dependent absorption Lansoprazole may interfere with the absorption of other medicinal products where gastric pH is an important determinant of oral bioavailability HIV Protease Inhibitors: Co-administration of lansoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH, such as atazanavir, and nelfinavir, due to significant reduction in their bioavailabilit

Can Zalanzo be used during pregnancy?

Pregnancy: There is limited amount of data from the use of lansoprazole in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. As a precautionary measure, it is preferable to avoid, the use of lansoprazole during pregnancy. Breastfeeding: It is not known whether lansoprazole is excreted in human breast milk. Animal studies have shown excretion of lansopra

Who manufactures Zalanzo?

Exeltis Poland Sp. z o.o. (Hiszpania)

What ATC class does Zalanzo belong to?

Zalanzo: ATC A02BC03. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

Zalanzo

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

Zalanzo — Description, Dosage, Side Effects | PillsCard

Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC03 Lansoprazole is a gastric proton pump inhibitor.‍‍‍‍‍‍‍ It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid. Lansoprazole is concentrated in the parietal cells and becomes active in their acidic environment, whereupon it reacts with the sulphydryl group of H+/K+ATPase causing inhibition of the enzyme activity. Effect on gastric acid secretion: Lansoprazole is a specific inhibitor of the parietal cell proton pump. A single oral dose of lansoprazole inhibits pentagastrin-stimulated gastric acid secretion by about 80%. After repeated daily administration for seven days, about 90% inhibition of gastric acid secretion is achieved. It has a corresponding effect on the basal secretion of gastric acid. A single oral dose of 30 mg reduces basal secretion by about 70%, and the patients' symptoms are consequently relieved starting from the very first dose. After eight days of repeated administration the reduction is about 85%. A rapid relief of symptoms is obtained by one capsule (30 mg) daily, and most patients with duodenal ulcer recover within 2 weeks, patients with gastric ulcer and reflux oesophagitis within 4 weeks. By reducing gastric acidity, lansoprazole creates an environment in which appropriate antibiotics can be effective against H. pylori. During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.

Zalanzo

User Reviews